Caplin Steriles, a wholly-owned subsidiary of Caplin Point Laboratories , has received the Establishment Inspection Report from the US Food and Drug Administration for the recently concluded inspection in June. This was the third successful US FDA audit of the plant since 2016, the company said in a statement to the exchanges. Shares of Caplin Point jumped 10.30 per cent at ₹425.80 on the BSE.
Caplin Steriles gets USFDA EIR
Published on
July 25, 2019 16:28
Tags